Italia markets closed

Dow Jones
39.997,58
-6,01(-0,02%)
Nasdaq
16.789,65
+103,69(+0,62%)
Nikkei 225
39.069,68
+282,30(+0,73%)
EUR/USD
1,0864
-0,0008(-0,08%)
Bitcoin EUR
62.178,71
+608,11(+0,99%)
CMC Crypto 200
1.375,28
+20,86(+1,54%)

NVCR Jan 2026 20.000 call

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

9,01

0,00

(0,00%)

In data: 01:55PM EDT. Mercato aperto.

GlobeNewswire
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpoint inhibitors resulted in an unprecedented 8-month improvement in median overall survival LUNAR is the first phase 3 clinical trial in more than seven years to show a significant extension in overall survival in